AAPL342.21+0.21 (+0.06%) ▲|ABBV285.04+1.64 (+0.58%) ▲|ABT104.56-0.12 (-0.11%) ▼|ACN226.79+1.87 (+0.83%) ▲|ADBE245.41-6.26 (-2.49%) ▼|AMAT416.22-13.79 (-3.21%) ▼|AMD540.97-21.26 (-3.78%) ▼|AMGN435.21+1.18 (+0.27%) ▲|AMT184.49+3.13 (+1.73%) ▲|AMZN253.39-1.37 (-0.54%) ▼|AVGO333.96-10.37 (-3.01%) ▼|AXP316.28+2.41 (+0.77%) ▲|BA189.00+0.27 (+0.14%) ▲|BAC52.14+0.44 (+0.85%) ▲|BKNG165.75-0.06 (-0.03%) ▼|BLK1,135.44+14.66 (+1.31%) ▲|BMY60.60+0.03 (+0.05%) ▲|BNY143.30+1.21 (+0.85%) ▲|BRK-B529.60+3.92 (+0.74%) ▲|C125.41+2.20 (+1.78%) ▲|CAT737.56+1.92 (+0.26%) ▲|CL93.70+1.03 (+1.11%) ▲|CMCSA22.25+0.48 (+2.18%) ▲|COF201.81+2.95 (+1.48%) ▲|COP144.70+2.97 (+2.10%) ▲|COST990.58+12.57 (+1.29%) ▲|CRM239.28-7.46 (-3.02%) ▼|CSCO108.10-1.76 (-1.60%) ▼|CVS92.88+0.30 (+0.32%) ▲|CVX222.51+3.19 (+1.45%) ▲|DE641.25-9.42 (-1.45%) ▼|DHR230.18-1.33 (-0.57%) ▼|DIS111.59+0.91 (+0.82%) ▲|DUK120.86+1.98 (+1.67%) ▲|EMR161.70-0.45 (-0.28%) ▼|FDX292.73-2.82 (-0.95%) ▼|GD341.67+4.64 (+1.38%) ▲|GE317.07+5.07 (+1.63%) ▲|GEV928.95+2.51 (+0.27%) ▲|GILD156.37-1.00 (-0.64%) ▼|GM84.92+1.26 (+1.51%) ▲|GOOG339.95-4.96 (-1.44%) ▼|GOOGL343.72-5.50 (-1.57%) ▼|GS890.30-0.98 (-0.11%) ▼|HD312.36+4.12 (+1.34%) ▲|HON211.93+1.43 (+0.68%) ▲|IBM231.76-2.36 (-1.01%) ▼|INTC91.16-4.22 (-4.42%) ▼|INTU323.04-7.13 (-2.16%) ▼|ISRG429.27+1.41 (+0.33%) ▲|JNJ255.45+2.17 (+0.85%) ▲|JPM341.07+5.54 (+1.65%) ▲|KO93.38+1.38 (+1.50%) ▲|LIN498.82+5.60 (+1.14%) ▲|LLY1,262.18+10.57 (+0.84%) ▲|LMT544.12+11.48 (+2.16%) ▲|LOW198.24+2.52 (+1.29%) ▲|LRCX268.61-8.86 (-3.19%) ▼|MA617.04+0.72 (+0.12%) ▲|MCD243.43+0.93 (+0.38%) ▲|MDLZ64.12+1.09 (+1.73%) ▲|MDT94.70-0.75 (-0.79%) ▼|META720.00-16.72 (-2.27%) ▼|MMM164.77-0.57 (-0.34%) ▼|MO74.76+0.92 (+1.24%) ▲|MRK146.74+1.55 (+1.07%) ▲|MS182.61+0.51 (+0.28%) ▲|MSFT528.56-10.88 (-2.02%) ▼|MU895.72-35.52 (-3.81%) ▼|NEE79.92+0.96 (+1.22%) ▲|NFLX70.82-1.79 (-2.47%) ▼|NKE37.44+0.30 (+0.81%) ▲|NOW140.11-8.46 (-5.69%) ▼|NVDA217.01-0.22 (-0.10%) ▼|ORCL129.62-4.86 (-3.61%) ▼|PEP131.21+2.83 (+2.20%) ▲|PFE29.59+0.15 (+0.49%) ▲|PG159.22+2.14 (+1.36%) ▲|PLTR187.33-13.18 (-6.57%) ▼|PM204.24+4.34 (+2.17%) ▲|QCOM176.07-2.33 (-1.31%) ▼|RTX191.39+4.44 (+2.38%) ▲|SBUX97.08+0.20 (+0.20%) ▲|SCHW92.40-1.76 (-1.87%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.92+1.53 (+0.75%) ▲|T23.64+0.14 (+0.57%) ▲|TMO686.16-10.33 (-1.48%) ▼|TMUS158.50+1.47 (+0.94%) ▲|TSLA358.11-4.33 (-1.20%) ▼|TXN281.87+2.75 (+0.99%) ▲|UBER70.67-0.61 (-0.85%) ▼|UNH400.94-5.74 (-1.41%) ▼|UNP287.74-0.98 (-0.34%) ▼|UPS97.28-0.55 (-0.56%) ▼|USB58.40+1.01 (+1.76%) ▲|V402.47+2.72 (+0.68%) ▲|VZ44.74+0.34 (+0.75%) ▲|WFC83.79+1.04 (+1.26%) ▲|WMT118.37+0.50 (+0.42%) ▲|XOM176.64+1.96 (+1.12%) ▲|AAPL342.21+0.21 (+0.06%) ▲|ABBV285.04+1.64 (+0.58%) ▲|ABT104.56-0.12 (-0.11%) ▼|ACN226.79+1.87 (+0.83%) ▲|ADBE245.41-6.26 (-2.49%) ▼|AMAT416.22-13.79 (-3.21%) ▼|AMD540.97-21.26 (-3.78%) ▼|AMGN435.21+1.18 (+0.27%) ▲|AMT184.49+3.13 (+1.73%) ▲|AMZN253.39-1.37 (-0.54%) ▼|AVGO333.96-10.37 (-3.01%) ▼|AXP316.28+2.41 (+0.77%) ▲|BA189.00+0.27 (+0.14%) ▲|BAC52.14+0.44 (+0.85%) ▲|BKNG165.75-0.06 (-0.03%) ▼|BLK1,135.44+14.66 (+1.31%) ▲|BMY60.60+0.03 (+0.05%) ▲|BNY143.30+1.21 (+0.85%) ▲|BRK-B529.60+3.92 (+0.74%) ▲|C125.41+2.20 (+1.78%) ▲|CAT737.56+1.92 (+0.26%) ▲|CL93.70+1.03 (+1.11%) ▲|CMCSA22.25+0.48 (+2.18%) ▲|COF201.81+2.95 (+1.48%) ▲|COP144.70+2.97 (+2.10%) ▲|COST990.58+12.57 (+1.29%) ▲|CRM239.28-7.46 (-3.02%) ▼|CSCO108.10-1.76 (-1.60%) ▼|CVS92.88+0.30 (+0.32%) ▲|CVX222.51+3.19 (+1.45%) ▲|DE641.25-9.42 (-1.45%) ▼|DHR230.18-1.33 (-0.57%) ▼|DIS111.59+0.91 (+0.82%) ▲|DUK120.86+1.98 (+1.67%) ▲|EMR161.70-0.45 (-0.28%) ▼|FDX292.73-2.82 (-0.95%) ▼|GD341.67+4.64 (+1.38%) ▲|GE317.07+5.07 (+1.63%) ▲|GEV928.95+2.51 (+0.27%) ▲|GILD156.37-1.00 (-0.64%) ▼|GM84.92+1.26 (+1.51%) ▲|GOOG339.95-4.96 (-1.44%) ▼|GOOGL343.72-5.50 (-1.57%) ▼|GS890.30-0.98 (-0.11%) ▼|HD312.36+4.12 (+1.34%) ▲|HON211.93+1.43 (+0.68%) ▲|IBM231.76-2.36 (-1.01%) ▼|INTC91.16-4.22 (-4.42%) ▼|INTU323.04-7.13 (-2.16%) ▼|ISRG429.27+1.41 (+0.33%) ▲|JNJ255.45+2.17 (+0.85%) ▲|JPM341.07+5.54 (+1.65%) ▲|KO93.38+1.38 (+1.50%) ▲|LIN498.82+5.60 (+1.14%) ▲|LLY1,262.18+10.57 (+0.84%) ▲|LMT544.12+11.48 (+2.16%) ▲|LOW198.24+2.52 (+1.29%) ▲|LRCX268.61-8.86 (-3.19%) ▼|MA617.04+0.72 (+0.12%) ▲|MCD243.43+0.93 (+0.38%) ▲|MDLZ64.12+1.09 (+1.73%) ▲|MDT94.70-0.75 (-0.79%) ▼|META720.00-16.72 (-2.27%) ▼|MMM164.77-0.57 (-0.34%) ▼|MO74.76+0.92 (+1.24%) ▲|MRK146.74+1.55 (+1.07%) ▲|MS182.61+0.51 (+0.28%) ▲|MSFT528.56-10.88 (-2.02%) ▼|MU895.72-35.52 (-3.81%) ▼|NEE79.92+0.96 (+1.22%) ▲|NFLX70.82-1.79 (-2.47%) ▼|NKE37.44+0.30 (+0.81%) ▲|NOW140.11-8.46 (-5.69%) ▼|NVDA217.01-0.22 (-0.10%) ▼|ORCL129.62-4.86 (-3.61%) ▼|PEP131.21+2.83 (+2.20%) ▲|PFE29.59+0.15 (+0.49%) ▲|PG159.22+2.14 (+1.36%) ▲|PLTR187.33-13.18 (-6.57%) ▼|PM204.24+4.34 (+2.17%) ▲|QCOM176.07-2.33 (-1.31%) ▼|RTX191.39+4.44 (+2.38%) ▲|SBUX97.08+0.20 (+0.20%) ▲|SCHW92.40-1.76 (-1.87%) ▼|SO90.69+1.51 (+1.69%) ▲|SPG204.92+1.53 (+0.75%) ▲|T23.64+0.14 (+0.57%) ▲|TMO686.16-10.33 (-1.48%) ▼|TMUS158.50+1.47 (+0.94%) ▲|TSLA358.11-4.33 (-1.20%) ▼|TXN281.87+2.75 (+0.99%) ▲|UBER70.67-0.61 (-0.85%) ▼|UNH400.94-5.74 (-1.41%) ▼|UNP287.74-0.98 (-0.34%) ▼|UPS97.28-0.55 (-0.56%) ▼|USB58.40+1.01 (+1.76%) ▲|V402.47+2.72 (+0.68%) ▲|VZ44.74+0.34 (+0.75%) ▲|WFC83.79+1.04 (+1.26%) ▲|WMT118.37+0.50 (+0.42%) ▲|XOM176.64+1.96 (+1.12%) ▲|
18.5 C
New York
Friday, October 16, 2026

Tag: inhibitor

newssourceFORcompanycontentinformation1releasesmarket

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across...

Sebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive Reflux Disease (NERD) at the American College of Gastroenterology (ACG) 2026 Meeting

Key Highlights:Tegoprazan is the first and only P-CAB reported to demonstrate clinical improvement in both hallmark symptoms of NERD, heartburn and regurgitation, in a...

Prifemilast Demonstrates Superior Efficacy vs. Apremilast in Newsoara’s Head-to-Head Phase 3 Psoriasis Trial; cAMPfield Advancing the Potential Best-in-Class Oral PDE4 Inhibitor in IBD

In a head-to-head Phase 3 trial, prifemilast nearly doubled the rate of PASI 75 response compared with apremilast and achieved superiority on both co-primary...

Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Oct. 9, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...

Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Oct. 8, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...

Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026

–  PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer –– VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2...

Beactica Therapeutics selects BEA-28 as a preclinical candidate, a first-in-class TEAD degrader for biomarker-selected cancers

UPPSALA, Sweden, Oct. 6, 2026 /PRNewswire/ -- Beactica Therapeutics AB, a Swedish precision medicine company, today announced the selection of BEA-28 as a preclinical...

Mozart Therapeutics Presents Clinical and Preclinical Data Supporting MTX-101 at the 62nd EASD Annual Meeting

Presentations highlight Phase 1 clinical findings, proof-of-mechanism data, and translational evidence supporting the therapeutic potential of MTX-101 in adults and adolescents with Stage 3...

Tennessee American Water to Conduct Service Line Material Verification in its Citico Service District

Work planned in Chattanooga in the coming weeksCHATTANOOGA, Tenn., Sept. 15, 2026 /PRNewswire/ -- Tennessee American Water announced today that it will begin service...

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test

Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitisFRIENDSWOOD, Texas, July 14,...

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a...

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInhibitor

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers